Following completion of the merger with Pall, Danaher plans to split into two publicly traded companies.
Proceeds from the notes offering will be used to pay a portion of the $13.8 billion cost of acquiring Pall.
Upon completion of the deal, Danaher will split into two publicly traded firms, with the life sciences and diagnostics business contained in the company that will retain the Danaher name.
NEW YORK (GenomeWeb News) – Pall today announced an exclusive distribution deal covering India between Pall India and Spinchrom Life Sciences, a division of Spinco Biotech.
Pall last week launched a PCR-based test for microorganisms that cause beer spoilage.
Pall said last week that its GeneDisc assays for Listeria have received performance tested methods certification from the AOAC Research Institute.
By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Pall today said that it has signed an agreement to acquire protein analysis products firm ForteBio for an undisclosed sum.
A marketing executive for the company said that the GeneDisc system is the first qPCR-based platform on the market to simultaneously detect several indicator pathogens as required by the US Pharmacopeia.
Heiner Dreismann joins Myriad Genetics' board; Response Genetics names Michael McNulty as COO; Pall appoints Michael Egholm as CTO.
Michael Egholm, Todd Arnold, Heiner Dreismann
In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.
The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.
A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.
Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.